MedTrace Logo

Cross-over Study to Investigate Retinal Function Following Administration of a Single Dose of AZD9056

NCT00700986 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 12

Last updated 2010-12-01

No results posted yet for this study

Summary

The purpose of the study is to determine whether treatment with a single 800mg dose of AZD9056, a medication which has been developed as a possible treatment for Rheumatoid Arthritis, has an effect on the function of the retina

Conditions

Interventions

DRUG

AZD9056

Oral tablet, 800mg, one single administration

DRUG

Placebo

Single dose

Sponsors & Collaborators

Principal Investigators

  • William Fahy, MA, MBBS (Hons) · AstraZeneca Clinical Pharmacology Unit, Nottingham

  • Mark Layton, MD, MRCP (UK) · AstraZeneca Alderley Park

Study Design

Allocation
RANDOMIZED
Masking
DOUBLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2008-06-30
Primary Completion
2008-08-31
Completion
2008-08-31

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00700986 on ClinicalTrials.gov